MedTrace Logo

Effect of Kinesiotape on Emesis in Pregnant Women

NCT06625632 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-10-08

No results posted yet for this study

Summary

This study will be conducted to investigate the effect of kinesiotaping on emesis in pregnant women.

Conditions

  • Emesis Pregnancy

Interventions

DRUG

Antiemetic Drug

All participants in the two groups will receive antiemetic drugs (ondansetron 4 mg) every 12 hours, for 5 days.

DIETARY_SUPPLEMENT

Vitamin B6

All participants in the two groups will receive vitamin B6 (50 mg), once daily, for 5 days.

OTHER

Home care advice

All participants in both groups will be advised to eat small portions of food, drink plenty of liquids, and avoid fatty and fried foods. Additionally, they should steer clear of highly spiced foods, foods and beverages with strong odors, caffeine, and consume neither very hot nor very cold foods and liquids.

OTHER

Kinesiotaping

It will be applied for all participants in the experimental group only for 5 days. The participant will be asked to stand in erect position, her hands beside her body then applying the kinesiotape from origin (from top to bottom where the stomach is placed on the abdominal region) to insertion (alongside the gastric curvature) with tension 25% for 5 days.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Azza Barmoud Nashed Kassab, PhD · Professor, Cairo university

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-07
Primary Completion
2025-01-07
Completion
2025-01-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06625632 on ClinicalTrials.gov